Please assess the completion status of the following clinical trial:

Trial Title: A Multiple Oral Doses Study Of PF-06427878 In Healthy Adult Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male and/or female subjects of non childbearing potential.~* Body Mass Index (BMI) of 17.5 to 35.4 kg/m2; and a total body weight \>50 kg~* Subjects with fasting TG level of \>=90 mg/dL and \<=500 mg/dL following an overnight fast~* Subjects with low density lipoprotein cholesterol between 115 mg/dL and 190 mg/dL following an overnight fast~Exclusion Criteria:~•Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): Single dose level of PF-06427878 at 5 mg or placebo every 8 hours (Q8H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
- Cohort 2 (Type: EXPERIMENTAL): Single dose level of PF-06427878 at a dose no more than 3.5-fold increase from Cohort 1 or placebo every 8 hours (Q8H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
- Cohort 3 (Type: EXPERIMENTAL): Single dose level of PF-06427878 at a dose no more than 3.5-fold increase from Cohort 2 or placebo every 8 hours (Q8H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
- Cohort 4 (Type: EXPERIMENTAL): Single dose level of PF-06427878 at a dose no more than 3.5-fold increase from Cohort 3 or placebo every 8 hours (Q8H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
- Cohort 5 (Type: EXPERIMENTAL): Single dose level of PF-06427878 at a dose no more than 3.5-fold increase from Cohort 4 or placebo every 8 hours (Q8H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
- Cohort 6 (Type: EXPERIMENTAL): Single dose level of PF-06427878 (with the same total daily dose as Cohort 5) or placebo every 12 hours (Q12H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.

Based on this trial design, predict the completion outcome and termination type (if applicable).